Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Jianling Bi; Andreea M Newtson; Yuping Zhang; Eric J Devor; Megan I Samuelson; Kristina W Thiel; Kimberly K Leslie

doi:10.3390/cancers13122901

Back

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Journal article

Open access

Peer reviewed

Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing

Jianling Bi, Andreea M Newtson, Yuping Zhang, Eric J Devor, Megan I Samuelson, Kristina W Thiel and Kimberly K Leslie

Cancers, Vol.13(12), p.2901

06/02/2021

DOI: 10.3390/cancers13122901

PMCID: PMC8229222

PMID: 34200645

Files and links (1)

url

https://doi.org/10.3390/cancers13122901View

Published (Version of record) Open Access

Abstract

Developing reliable experimental models that can predict clinical response before treating the patient is a high priority in gynecologic cancer research, especially in advanced or recurrent endometrial and ovarian cancers. Patient-derived organoids (PDOs) represent such an opportunity. Herein, we describe our successful creation of 43 tumor organoid cultures and nine adjacent normal tissue organoid cultures derived from patients with endometrial or ovarian cancer. From an initial set of 45 tumor tissues and seven ascites fluid samples harvested at surgery, 83% grew as organoids. Drug sensitivity testing and organoid cell viability assays were performed in 19 PDOs, a process that was accomplished within seven days of obtaining the initial surgical tumor sample. Sufficient numbers of cells were obtained to facilitate testing of the most commonly used agents for ovarian and endometrial cancer. The models reflected a range of sensitivity to platinum-containing chemotherapy as well as other relevant agents. One PDO from a patient treated prior to surgery with neoadjuvant trastuzumab successfully predicted the patient’s postoperative chemotherapy and trastuzumab resistance. In addition, the PDO drug sensitivity assay identified alternative treatment options that are currently used in the second-line setting. Our findings suggest that PDOs could be used as a preclinical platform for personalized cancer therapy for gynecologic cancer patients.

Endometrial Cancer

Ovarian Cancer

Personalized Medicine

drug sensitivity testing

patient-derived organoids (PDOs)

Details

Title: Subtitle: Successful Patient-Derived Organoid Culture of Gynecologic Cancers for Disease Modeling and Drug Sensitivity Testing
Creators: Jianling Bi - University of Iowa
Andreea M Newtson - University of Iowa
Yuping Zhang - University of Iowa
Eric J Devor - University of Iowa
Megan I Samuelson - University of Iowa
Kristina W Thiel - University of Iowa
Kimberly K Leslie - University of Iowa
Resource Type: Journal article
Publication Details: Cancers, Vol.13(12), p.2901
DOI: 10.3390/cancers13122901
PMID: 34200645
PMCID: PMC8229222
NLM abbreviation: Cancers (Basel)
ISSN: 2072-6694
eISSN: 2072-6694
Publisher: MDPI
Grant note: DOI: 10.13039/100000002, name: National Institutes of Health, award: R01CA099908, P30CA086862; DOI: 10.13039/100000005, name: U.S. Department of Defense, award: OC190352; DOI: 10.13039/100006108, name: National Center for Advancing Translational Sciences, award: UL1TR002537
Language: English
Date published: 06/02/2021
Academic Unit: Pathology; Radiation Oncology; Obstetrics and Gynecology
Record Identifier: 9984186560302771

Metrics

10 Record Views

55 Times Cited - Web of Science